VEXAS syndrome : literature review.

Read full text Summarise with VIRAT
Authors: Abdelhak ABABSA MOUAKI, Ouassila ABBASI
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

VEXAS is an acronym standing for vacuoles, enzyme E1, X-linked, autoinflammatory, and somatic. It designates an autoinflammatory syndrome in adults, first described in 2020, linked to acquired somatic mutations in the UBA1 gene (ubiquitin-activating enzyme E1), located on the X chromosome and restricted to the hematopoietic compartment. The syndrome primarily affects men over 50 years of age, combining systemic inflammatory manifestations with suggestive hematological abnormalities. VEXAS syndrome should be considered in male patients presenting with incomplete or complete features of relapsing polychondritis, polyarteritis nodosa, giant cell arteritis, or Sweet’s syndrome — particularly when refractory to treatment and associated with hematological involvement such as cytopenias, myelodysplastic syndrome, or thromboembolic disease. Diagnosis relies on the identification of pathogenic variants of UBA1 — primarily p.Met41 — in blood or bone marrow. Management remains poorly defined and is based on two complementary approaches: anti-inflammatory treatment (corticosteroids, tocilizumab, JAK inhibitors) and/or targeting of the mutated hematopoietic clone (azacitidine, allogeneic hematopoietic stem cell transplantation), combined with appropriate supportive care.

Fields of Study & Subjects

Otitis Media and Relapsing Polychondritis Immunodeficiency and Autoimmune Disorders Autoimmune and Inflammatory Disorders

Publication details

Journal / source
Batna Journal of Medical Sciences (BJMS)
Volume
13
Issue
4
Publication date
1 April 2026
Language
EN